Home
Conferences
Events
Media
Publications
Resources
NCCN
ASCO
Hematology
Sign In
Home
Conferences
Events
Media
Publications
Resources
Search
Home
Conferences
Events
Media
Publications
Resources
NCCN
ASCO
Hematology
Trending →
T-DXd Plus Pertuzumab Receives FDA Approval, Shifting the Frontline HER2-Positive Paradigm
By
MedOnc2
December 15, 2025
FDA Approves Niraparib Plus Abiraterone Acetate and Prednisone for BRCA2-Mutated mCSPC
By
MedOnc2
December 15, 2025
FDA Approves Durvalumab for Resectable Gastric and Gastroesophageal Junction Adenocarcinoma
By
MedOnc2
December 15, 2025
FDA Grants Traditional Approval to Pirtobrutinib (Jaypirca®) for CLL/SLL
By
MedOnc2
December 15, 2025
Enfortumab Vedotin + Pembrolizumab for Muscle-Invasive Bladder Cancer (MIBC)
By
MedOnc2
November 22, 2025
Login
Sign In
Follow US
MedOnc2
Follow:
21
Articles
T-DXd Plus Pertuzumab Receives FDA Approval, Shifting the Frontline HER2-Positive Paradigm
December 15, 2025
FDA Approves Niraparib Plus Abiraterone Acetate and Prednisone for BRCA2-Mutated mCSPC
December 15, 2025
FDA Approves Durvalumab for Resectable Gastric and Gastroesophageal Junction Adenocarcinoma
December 15, 2025
FDA Grants Traditional Approval to Pirtobrutinib (Jaypirca®) for CLL/SLL
December 15, 2025
Enfortumab Vedotin + Pembrolizumab for Muscle-Invasive Bladder Cancer (MIBC)
November 22, 2025
Imdelltra for Relapsed Extensive-Stage Small Cell Lung Cancer
November 20, 2025
Epcoritamab-bysp for Follicular Lymphoma
November 19, 2025
Ziftomenib for NPM1-Mutated R/R AML
November 13, 2025
FDA Approves Blenrep in Relapsed/Refractory Multiple Myeloma
November 11, 2025
FDA Approves Daratumumab for High-Risk Smoldering Multiple Myeloma
November 11, 2025
Oral SERD FDA approval
September 29, 2025
New approval for Immune Thrombocytopenia (ITP)
September 23, 2025
Show More
